Abstract 164P
Background
5-Fluorouracil (5-FU) is a key drug in treatment of unresectable advanced gastric cancer (AGC). It is known that intravenous 5-FU and oral fluorouracil have different mechanism as anti-cancer drugs, however, a clinical benefit of intravenous 5-FU after using oral fluorouracil is not clear. Therefore, we planned a prospective study to assess the efficacy and safety of weekly intravenous 5-FU and l-leucovorin(l-LV) in Japanese patients with AGC which was resistant for oral fluorouracil, taxane, and platinum. This encore abstract was previously reported at the ESMO 21st World Congress on Gastrointestinal Cancer 2019; the abstract number was P-176.
Methods
This regimen consisted of l-LV 250mg/m2/2h iv and 5-FU 600mg/m2 iv once a week for 6 weeks followed by 2-week rest period, within an 8-week cycle. The primary endpoint was the progression free survival (PFS) rate at 8 weeks.
Results
Among the 29 enrolled patients, PFS rate at 8 weeks was 55.2% (95% CI 35.6% to 71.0%), which was higher than 47.5% which is the expected value of the hypothesis, and the lower limit of 95% CI is significantly higher than the threshold which is 23.1%. Grade 3 to 4 hematological adverse events (AE) were as follows; anemia 20.7%, neutropenia 3.4%, and platelet count decreased 3.4%. Grade 3 to 4 non-hematological AE were observed as follows; anorexia 20.7%, fatigue 13.8%, and diarrhea 3.4%.
Conclusions
The intravenous 5-FU and l-LV regimen is feasible and could be promising as the salvage line treatment in patients with AGC even if that is resistant for oral fluorouracil, taxane and platinum.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The Helsinki Ethical Principles (revised in Oct, 2013) and the Ethical Guidelines for Medical and Health Research involving in Human Subjects in 2014.
Funding
Hokkaido Gastrointestinal Cancer Study Group.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract